SARTORIUS AG Goettingen, December 18, 2014 - The Sartorius Group, a leading international laboratory and biopharmaceutical equipment provider, took out a long-term syndicated loan of 400 million euros for the next five years. Yesterday, the company signed the loan agreement with an international bank syndicate led by BNP Paribas, Commerzbank and LBBW. This new agreement replaces the two previously separate credit contracts ahead of schedule.
Based on this transaction, Sartorius is consolidating credit lines for financing within the Group. Until now, one of the former credit lines taken out had been available only to the subgroup Sartorius Stedim Biotech. "The new credit agreement enables us to invest flexibly in our various business areas and provides leeway for taking further strategic measures," commented Jörg Pfirrmann, CFO and member of the Executive Board of Sartorius. "We were able to conclude this agreement under highly attractive terms and conditions. On the one hand, such conditions are a consequence of the low interest environment and, on the other hand, they also reflect the confidence that banks have in the financial strength of and in the positive prospects for Sartorius and Sartorius Stedim Biotech."
This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.
|
distributed by
|
